Methods: Twenty-two individuals with APS with or without other associated autoimmune disease (20 females, two males, median age 55 (range 18-70) years) had blood samples taken before and 12 weeks after starting HCQ 200mg. Plasma was stored at -80 o C and thawed to measure TF using Imubind TF kit (Invitech Ltd, Cambridgeshire, UK). The assay was performed according to the manufacturer's instructions. Patient characteristics are outlined in table 1. Statistical analysis was performed using SPSS Version 22. For continuous normally distributed data a two-tailed student's paired t-test was performed. A value of p=0.05 was considered as significant. There are no previous data in this area, so we were unable to do a power calculation to work out study size. Our study is therefore a pilot study. Results: Soluble TF levels were above our normal range (40-300 pg/ml) prior to the commencement of HCQ and were significantly reduced (pre level mean (SD) 401.8 (152.8) pg/ml versus post 300.9 (108) pg/ml (p=0.010).
AB0148 INDUCTION OF HO-1 EXPRESSION IN MONOCYTES MIGHT PREVENT KIDNEY DAMAGE IN LUPUS NEPHRITIS (LN)
Background: Systemic lupus erythematous (SLE), is an autoimmune disease characterized by autoantibody synthesis and inflammation. During disease course, up to 70% of SLE patients will develop LN. Emerging evidence has demonstrated that infiltrating monocytes and macrophages are associated with LN pathogenesis. We have previously demonstrated that HO-1, a haem-degrading enzyme with anti-inflammatory properties is decreased in peripheral monocytes of SLE patients. Therefore, we decided to explore the contribution of HO-1 expression to LN pathogenesis.
Objectives:
To explore the role of HO-1 in modulating innate immunity through a cytoprotective effect in monocytes of LN nephritis patients. Accordingly, we examined the expression of HO-1 in circulating monocytes, and the effect of HO-1 induction in reactive oxygen species (ROS) production and the phagocytic activity of monocytes from peripheral blood of LN patients and healthy controls (HC). Methods: SLE patients with proliferative LN confirmed by renal biopsy (Class III, IV or V ISN/RPS) were recruited at Hospital Clinico of PUC. All individuals signed an informed consent form. Monocytes were purified from peripheral blood mononuclear cells (PBMCs) of LN patients and HC using pan-monocytes MACS kit. Subpopulations of monocytes and HO-1 expression were measured by FACS. ROS was determined using CellRox Kit. The phagocytic ability of monocytes was assessed by FACS and the total phagocytosis was calculated as the percentage of cells with engulfed beads. Results: We found that monocytes from LN patients show significant differences when compared to HC in all the parameters analyzed. The percentage of CD16+ inflammatory monocytes was higher in LN patients (6.72±0.98%) compared to HC (4.07±0.48%) (p<0.05). HO-1 protein expression is decreased in circulating LN monocytes (4789±911 vs 1572±481, p=0.005). Baseline levels of ROS are elevated in LN monocytes with similar values that the ones found in monocytes from HC treated with a ROS inducer (HC: 3509±584; HC+TBHP: 8436±1909; LN: 8355±1714). Furthermore, phagocytic activity is increased in LN monocytes (77.97±3.31%) compared to HC (39.63±2.75%). Moreover, our preliminary data indicate that HO-1 induction, using cobalt protoporphyrin (CoPP), leads to downregulation of ROS production in LN (∼60%) and HC (∼40%) leaving both in similar levels of ROS production. In addition, phagocytic activity is also decreased in LN and HC monocytes in the presence of CoPP (∼30%). Conclusions: Decreased HO-1 expression in circulating monocytes of LN patients leads to higher ROS production and phagocitic activity. ROS level and phagocytosis are reduced when we induce HO-1 expression with CoPP. We propose that HO-1 induction might exert a cytoprotective role in LN by regulating innate immunity. FONDECYT N°1150173. Acknowledgements: We would like to extend our appreciation to all the volunteers that participated in this study. Disclosure of Interest: None declared DOI: 10.1136/annrheumdis-2017-eular.6428 Background: Systemic Lupus Erythematosus (SLE) is a prototype of autoinmune diseases with excessive anti-nuclear autoantibodies production. B cells activation with immune complex formation is the main characteristic of SLE with abnormalities in immune cells, dysregulation of apoptosis, and defects in the clearance of apoptotic materials. Autophagy, a highly conserved protein degradation pathway, is essential for removing protein aggregates and misfolded proteins in cells and its defects contributes to SLE pathogenesis. On the other hand, multiple evidences in humans and experimental models suggest that prolactin (PRL) is associated with active SLE and participates in the immune dysregulation, and one of the mechanisms of PRL action is the inhibition of apoptosis. Objectives: Analyze the relationship between PRL receptors (PRL-R) on B cells and markers of autophagy on T regulatory cells and the association, if any, with clinical characteristics of SLE.
AB0149 PROLACTIN AND AUTOPHAGY IN SYSTEMIC LUPUS ERYTHEMATOSUS: CLINICAL SIGNIFICANCE OF CORRELATION BETWEEN PRL-R+ (RECEPTOR), CD19+, ATG14+, AND CD25+ EXPRESSION ON B AND T REGULATORY CELLS

Methods:
The expression of PRL-R on B cells CD19 + , and autophagy-related key regulator protein ATG14 + , on T regulatory cells CD25 + , were measured by flow cytometry, and expressed in percentages of SLE patients (1997, ACR criteria), and healthy controls. Active SLE was considered by SLEDAI (≥4). The organs affected and treatments were evaluated. Results: A total of 40 SLE patients and 20 healthy controls were included. Mean age of patients and controls was 30.67±4.16. Mean duration of disease was 6±4.6 years. Twenty patients were active (SLEDAI 8.45±1.9) and of these, lupus glomerulonephritis was observed in 13 patients (65%). The expression of PRL-R on B cells of active SLE was higher than in inactive SLE (50.5% vs 26.5%). In active SLE especially in patients with glomerulonephritis, the mean amount of PRL-R on B cells/ml was 6,645/ml (range 3167-6957). In contrast, patients with inactive SLE, had a low amount of PRL-R, 522.5/ml (range 15-895). In the relation of autophagy, the mean expression of ATG14 + in 20 active SLE patients was 11.19% in comparison with inactive SLE patients, 7.13%, (p=0.04), and in healthy donors, 7.445% (p=0.0281). Conclusions: Our study suggest: In active SLE patients the expression of PRL-R and autophagy-related key regulator protein ATG14+ are very high in B cells and T regulators respectively, in comparison with inactive SLE and healthy donors. These novel findings suggest the interaction between PRL-R and autophagy in order to promote clinical/immune activation with overproduction of autoantibodies. PRL-R and ATG14 + may be a new target of SLE treatment. Background: Erythrocytes (RBCs) hold a crucial role in hemostasis and their integrity is influenced by different stimuli including circulating inflammatory mediators. Even though RBCs do not have nuclei and mitochondria, they have developed a process allowing them to undergo a rapid self-destruction named eryptosis. The exact mechanism of erythrocytes cell death is not fully clarified yet but it seems to involve Ca 2+ and ceramide formation, leading to cell shrinkage and externalization of phosphatidylserine (PS) (1). Interaction between platelets and erythrocytes could participate in an increasing risk of thrombotic episodes typical of several diseases including antiphospholipid syndrome (APS). In fact, not only signals triggering eryptosis are involved in thrombosis activation, but also recent studies have demonstrated how PS-exposing erythrocytes are able to adhere to the vascular wall causing an impairment of circulation (2,3). Objectives: Enhanced eryptosis is known to contribute to several pathological conditions (1) but the involvement of this process in APS has not been investigated yet. For this reason the aim of the study was to evaluate eryptosis levels in APS, healthy subjects positive for antiphospolipid antibodies without clinical manifestations (aPL carriers), autoimmune haemolytic anaemia (AIHA) and healthy donors (HD). Methods: 27 patients with primary APS (M/F 5/22, mean age 51.1±7.6 years), 14 aPL carriers (M/F 3/11, mean age 48.9±8.4 years) were recruited after written informed consent. Moreover 10 AIHA patients and 12 HD were also enrolled as positive and negative control group respectively. RBCs were isolated from whole blood after centrifugation and eryptosis levels were analysed by flow cytometry, evaluating the percentage of annexin V-positive cells (PS-exposing cells). Flow cytometry was also use to estimated cellular volume from forward scatter (FSC). Results: APS patients showed higher levels of eryptosis compared to HD (p=0.01). Interestingly, the percentage of annexin V-positive RBCs was lower in aPL carriers respect to APS patients (p=0.001). Moreover, an inverse correlation between RBCs volume and eryptosis was found in APS patients (r=-0.4, p=0.03) . No clinical correlation between eryptosis and clinical manifestations were noticed. As expected, eryptosis was upregulated in AIHA patients compared to all populations studied (p<0.0001). Conclusions: Our study provides for the first time evidence of eryptosis enhancement in APS patients suggesting a possible contribution of RBCs apoptosis in the pathogenesis of the disease. 
